Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2024 Oct 10

PMID 39386037

Authors

Zhen Ruan

Xianwen Chen

Menghuan Song

Ruxu Jia

Hang Luo

Carolina Oi Lam Ung

Hao Hu

Affiliations

Soon will be listed here.

Abstract

Aim: This study aimed to conduct a retrospective observational study in China to investigate the real-world utilization of glucagon-like peptide-1 receptor (GLP-1RA) in China.

Methods: Type 2 diabetes mellitus (T2DM) patients were retrieved from the electronic medical records of 18 hospitals from 2016 to 2020. A descriptive analysis detailed patient characteristics and clinical outcomes. Multivariate logistic regression analysed the factors associated with daily and weekly GLP-1RA.

Results: Fifteen thousand one hundred and seventy-six individuals were included. At the 6-month follow-up, the overall estimated mean change from baseline in HbA1c was -1.26±1.91% (p < 0.001), the "Weekly GLP-1RA" group was -1.58±2.03% (p < 0.001), and the "Daily GLP-1RA" group was -1.25±1.90% (p < 0.001). At the 12-month follow-up, the overall estimated mean change from baseline in HbA1c was -0.95±1.80% (p < 0.001), the "Weekly GLP-1RA" group was -1.05±1.93% (p < 0.001), and the "Daily GLP-1RA" group was -0.95±1.80% (p < 0.001). At 6 months following GLP-1RA initiation, there were statistically significant improvements in the mean TC, LDL-C, and TG at 6 months or 12 months separately following GLP-1RA initiation. Statistically significant improvements were observed in the mean HDL-C after 6 months. Compared with the baseline (11.92%), the proportion of patients who had an incidence of all hypoglycemia was lower at the 6-month follow-up (9.73%). Patients with dyslipidemia were more likely to use weekly GLP-1RA (OR =1.61, 95% CI: 1.27-2.06, p < 0.001).

Conclusion: In China, weekly GLP-1RA demonstrated better effectiveness compared to the daily GLP-1RA. The results confirmed the efficacy of GLP-1RA in clinical trials.

Citing Articles

Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.

Hu Y, Chen X, Zou H, Zhang H, Ni Q, Li Y Adv Ther. 2024; 42(2):904-917.

PMID: 39680313 DOI: 10.1007/s12325-024-03082-7.

References

Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y . Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol. 2017; 12(1):62-69.e1. DOI: 10.1016/j.jacl.2017.11.006. View

Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X . Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes Obes Metab. 2016; 18(8):803-11. PMC: 5084818. DOI: 10.1111/dom.12674. View

Hauber A, Nguyen H, Posner J, Kalsekar I, Ruggles J . A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2015; 32(2):251-62. DOI: 10.1185/03007995.2015.1117433. View

Johnson C, Sussman W, Weeda E . Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis. Diabetes Obes Metab. 2024; 26(10):4544-4550. DOI: 10.1111/dom.15809. View

Gu K, Cowie C, Harris M . Diabetes and decline in heart disease mortality in US adults. JAMA. 1999; 281(14):1291-7. DOI: 10.1001/jama.281.14.1291. View

Dungan K, Tofe Povedano S, Forst T, Gonzalez J, Atisso C, Sealls W . Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951):1349-57. DOI: 10.1016/S0140-6736(14)60976-4. View

Alsugair H, Alshugair I, Alharbi T, Bin Rsheed A, Tourkmani A, Al-Madani W . Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. Healthcare (Basel). 2021; 9(9). PMC: 8466858. DOI: 10.3390/healthcare9091125. View

Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L . Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes Endocrinol. 2019; 8(1):13-14. DOI: 10.1016/S2213-8587(19)30382-1. View

Nauck M, Meier J . MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019; 181(6):R211-R234. DOI: 10.1530/EJE-19-0566. View

10.

Branch M, German C, Bertoni A, Yeboah J . Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J Diabetes Complications. 2019; 33(7):468-472. DOI: 10.1016/j.jdiacomp.2019.04.004. View

11.

Lopez-Suarez A . Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism. 2018; 92:136-146. DOI: 10.1016/j.metabol.2018.10.013. View

12.

Ji L, Hu D, Pan C, Weng J, Huo Y, Ma C . Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med. 2013; 126(10):925.e11-22. DOI: 10.1016/j.amjmed.2013.02.035. View

13.

Ahmad E, Lim S, Lamptey R, Webb D, Davies M . Type 2 diabetes. Lancet. 2022; 400(10365):1803-1820. DOI: 10.1016/S0140-6736(22)01655-5. View

14.

Dar S, Siddiqi A, Alabduladhem T, Rashid A, Sarfraz S, Maniya T . Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. Ann Med Surg (Lond). 2022; 77:103633. PMC: 9142616. DOI: 10.1016/j.amsu.2022.103633. View

15.

Mali G, Ahuja V, Dubey K . Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther. 2020; 46(1):99-105. DOI: 10.1111/jcpt.13259. View

16.

Honigberg M, Chang L, McGuire D, Plutzky J, Aroda V, Vaduganathan M . Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol. 2020; 5(10):1182-1190. PMC: 7744318. DOI: 10.1001/jamacardio.2020.1966. View

17.

Su X, Hao Y, Liu J . Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors. Sci Rep. 2024; 14(1):18290. PMC: 11306237. DOI: 10.1038/s41598-024-69016-z. View

18.

Aschner P . New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017; 132:169-170. DOI: 10.1016/j.diabres.2017.09.002. View

19.

Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z . Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015; 37(1):225-241.e8. DOI: 10.1016/j.clinthera.2014.11.008. View

20.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View